Congress Materials – CHEST 2024

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Characteristics and outcomes of patients with pulmonary arterial hypertension and self-reported mental health comorbidities in the SPHERE (Selexipag: the users drug registry)

Vallerie McLaughlin, Harrison W. Farber, Kristin B. Highland, Nick H. Kim, Murali M. Chakinala, Kelly M. Chin, Michelle Han, Gurinderpal Doad, Paul Strachan, Michelle Cho, Tobore Tobore, Mohammad Rahman, and Anna R. Hemnes

 

View presentation slides

Characteristics and outcomes of patients with pulmonary arterial hypertension transitioning to selexipag from another prostacyclin pathway agent in the SPHERE registry

Murali M. Chakinala, Vallerie McLaughlin, Harrison W. Farber, Kristin B. Highland, MD, Anna R. Hemnes, Kelly M. Chin, Michelle Han, Gurinderpal Doad, Paul Strachan, Michelle Cho, Tobore Tobore, Mohammad Rahman, and Nick H. Kim

 

View presentation slides

Characteristics, treatment patterns, and outcomes of patients with pulmonary arterial hypertension by race: real-world data from the combined OPUS/ORPHEUS studies

McLaughlin VV, Channick R, Melendres-Groves L, Chin KM, MacDonald G, Martin N, Ong R, Sandros M, Kim NH, Gwen MacDonald

 

View presentation slides

Characteristics, treatment patterns, and outcomes of pulmonary arterial hypertension patients by ethnicity: real-world data from the combined OPUS/ORPHEUS studies

Melendres-Groves Chin KM, Kim NH, McLaughlin VV, MacDonald G, Martin N, Ong R, Sandros M, Channick R, Gwen MacDonald

 

View poster

Expert consensus exploring the definition of a disease-modifying therapy, and the data requirements to establish a therapy as disease-modifying in pulmonary arterial hypertension

Vallerie McLaughlin, Robert Frantz, Anna Hemnes, Franck Rahaghi, Sandeep Sahay, Michelle Cho, Gurinderpal Doad, Jenny Lam, David Lopez, Daisy Bridge, Ashley Enstone, Richard Perry, Lisa Perret, Holly Smith, Medi Stone, Paul Strachan

 

View poster

Expert consensus on the definition of methamphetamine-associated pulmonary arterial hypertension (Meth-APAH) and associated treatment considerations

Roham Zamanian, Nick Kim, Peter Leary, Therese Sargent, John Kingrey, Ankita Adhia, David Lopez, Ashley Enstone, Richard Perry, Daisy Bridge, Medi Stone, Lisa Perrett, Holly Smith , Marinella Sandros

 

View poster